Published in Hum Mol Genet on August 15, 2001
Genomewide association studies and human disease. N Engl J Med (2009) 9.05
High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet (2005) 6.86
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet (2010) 4.26
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat (2010) 2.29
Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 2.21
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet (2011) 2.12
The genetic epidemiology of neurodegenerative disease. J Clin Invest (2005) 2.08
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet (2002) 1.93
Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest (2003) 1.52
α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci (2010) 1.49
Head injury, α-synuclein genetic variability and Parkinson's disease. Eur J Neurol (2014) 1.48
Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse (2007) 1.41
Functional analysis of intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene. Hum Genet (2003) 1.38
Parkinson's disease and α-synuclein expression. Mov Disord (2011) 1.34
Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One (2009) 1.34
α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS One (2012) 1.33
Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am J Hum Genet (2005) 1.30
The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet (2003) 1.30
Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression. Nature (2016) 1.25
The alpha-synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry (2006) 1.25
Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx (2005) 1.22
Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiol Dis (2007) 1.22
Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet (2009) 1.21
Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol (2012) 1.14
Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat. Neurobiol Dis (2005) 1.13
Chasing genes in Alzheimer's and Parkinson's disease. Hum Genet (2004) 1.11
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem (2010) 1.11
Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma (2011) 1.08
Genetics and genomics of Parkinson's disease. Genome Med (2014) 1.04
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One (2012) 1.03
Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev Neurother (2010) 1.01
Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience (2009) 1.00
POLG1 polyglutamine tract variants associated with Parkinson's disease. Neurosci Lett (2010) 0.96
Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS One (2014) 0.92
The impact of genetic research on our understanding of Parkinson's disease. Prog Brain Res (2010) 0.90
SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. Parkinsonism Relat Disord (2011) 0.90
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
Genetic susceptibility in Parkinson's disease. Biochim Biophys Acta (2008) 0.89
Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One (2013) 0.88
Regulation of alpha-synuclein expression in alcohol-preferring and -non preferring rats. J Neurochem (2006) 0.87
Neurodegenerative disorders: Parkinson's disease and Huntington's disease. J Neurol Neurosurg Psychiatry (2005) 0.87
Key issues in essential tremor genetics research: Where are we now and how can we move forward? Tremor Other Hyperkinet Mov (N Y) (2013) 0.87
A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression. Alzheimers Dement (2015) 0.86
The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. J Neurochem (2016) 0.85
Beta-synuclein gene variants and Parkinson's disease: a preliminary case-control study. Neurosci Lett (2007) 0.85
Genetic variability in SNCA and Parkinson's disease. Neurogenetics (2011) 0.85
The H50Q mutation induces a 10-fold decrease in the solubility of α-synuclein. J Biol Chem (2014) 0.84
The genetic basis of Parkinson's disease. J Neurol Neurosurg Psychiatry (2002) 0.84
Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease Brain. Parkinsons Dis (2012) 0.83
Cerebrospinal fluid biomarker candidates for parkinsonian disorders. Front Neurol (2013) 0.83
Genomics and bioinformatics of Parkinson's disease. Cold Spring Harb Perspect Med (2012) 0.82
Merging mouse transcriptome analyses with Parkinson's disease linkage studies. DNA Res (2007) 0.81
Up-regulation of SNCA gene expression: implications to synucleinopathies. Neurogenetics (2016) 0.80
A prognostic view on the application of individualized genomics in Parkinson's disease. Curr Genet Med Rep (2013) 0.80
alpha-Synuclein promoter RsaI T-to-C polymorphism and the risk of Parkinson's disease. J Neural Transm (Vienna) (2006) 0.78
The PD-associated alpha-synuclein promoter Rep1 allele 2 shows diminished frequency in restless legs syndrome. Neurogenetics (2014) 0.78
Postmortem studies in Parkinson's disease. Dialogues Clin Neurosci (2004) 0.78
Whole-genome conditional two-locus analysis identifies novel candidate genes for late-onset Parkinson's disease. Neurogenetics (2009) 0.78
Festination Correlates with SNCA Polymorphism in Chinese Patients with Parkinson's Disease. Parkinsons Dis (2017) 0.77
Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease. Biomolecules (2015) 0.77
Discovery of functional non-coding conserved regions in the α-synuclein gene locus. F1000Res (2014) 0.77
Models of α-synuclein aggregation in Parkinson's disease. Acta Neuropathol Commun (2014) 0.77
Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast. FASEB J (2014) 0.76
Disease-Toxicant Interactions in Parkinson's Disease Neuropathology. Neurochem Res (2016) 0.76
Parkinson's disease: genetics and beyond. Curr Neuropharmacol (2007) 0.75
Identifying the genetic components underlying the pathophysiology of movement disorders. Appl Clin Genet (2011) 0.75
Exploring the Effects of Genetic Variants on Clinical Profiles of Parkinson's Disease Assessed by the Unified Parkinson's Disease Rating Scale and the Hoehn-Yahr Stage. PLoS One (2016) 0.75
Structural variants in SNCA gene and the implication to synucleinopathies. Curr Opin Genet Dev (2017) 0.75
Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA. Prog Neurobiol (2017) 0.75
Loss of MicroRNA-7 Regulation Leads to α-Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo. Mol Ther (2017) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol (2001) 14.57
Evidence for an extraterrestrial impact 12,900 years ago that contributed to the megafaunal extinctions and the Younger Dryas cooling. Proc Natl Acad Sci U S A (2007) 9.61
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry (2007) 6.72
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50
SOR: project methodology. Br J Cancer (2001) 5.24
Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 5.14
Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology (2007) 4.28
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature (1991) 3.86
Nucleotide sequence of the papA gene encoding the Pap pilus subunit of human uropathogenic Escherichia coli. J Bacteriol (1984) 3.73
Nanodiamonds in the Younger Dryas boundary sediment layer. Science (2009) 3.69
Prion dementia without characteristic pathology. Lancet (1990) 3.66
Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet (1993) 3.58
Genetics and psychiatry: past discoveries, current dilemmas, and future directions. Am J Psychiatry (1989) 3.35
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet (1992) 3.30
Verifying the stroke-free phenotype by structured telephone interview. Stroke (2000) 3.15
Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg (1969) 3.12
Cloning and sequencing of a Moraxella bovis pilin gene. J Bacteriol (1985) 3.10
A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet (2004) 3.05
Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking. EMBO J (1996) 3.04
Creutzfeldt-Jakob disease and blood transfusion. Lancet (1993) 2.97
Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med (1983) 2.88
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology (1999) 2.81
Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology (1999) 2.62
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology (2000) 2.31
Cell growth cycle block of T cell hybridomas upon activation with antigen. J Exp Med (1987) 2.30
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics (1997) 2.28
A full genome scan for late onset Alzheimer's disease. Hum Mol Genet (1999) 2.26
Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet (1998) 2.26
alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci (1999) 2.25
Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology (2007) 2.22
Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord (2000) 2.20
A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med (1998) 2.20
General practitioners' continuing education: a review of policies, strategies and effectiveness, and their implications for the future. Br J Gen Pract (1998) 2.20
Comparison of multivariate tests for genetic linkage. Hum Hered (2001) 2.19
Isolated eyelid-opening apraxia: report of a new levodopa-responsive syndrome. Neurology (1994) 2.14
Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med (1994) 2.10
Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology (2009) 2.09
Chromatin boundaries and chromatin domains. Cold Spring Harb Symp Quant Biol (2004) 2.08
Gamma-radiation sensitivity and risk of glioma. J Natl Cancer Inst (2001) 2.06
LRRK2 mutations in Parkinson disease. Neurology (2005) 2.01
Fatigue in patients with cancer. Eur J Cancer (1998) 1.99
Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology (2001) 1.98
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet (2005) 1.94
Carrier detection and prenatal diagnosis in Duchenne and Becker muscular dystrophy families, using dinucleotide repeat polymorphisms. Am J Hum Genet (1991) 1.93
Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax (2003) 1.93
Staphylococcus saprophyticus as a cause of urinary tract infections. J Clin Microbiol (1982) 1.91
Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nat Cell Biol (2000) 1.87
A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J Biol Chem (1999) 1.87
Links between passive smoking and disease: a best-evidence synthesis. A report of the Working Group on Passive Smoking. Clin Invest Med (1990) 1.87
The heritability and genetics of frontotemporal lobar degeneration. Neurology (2009) 1.86
Neisseria meningitidis produces iron-regulated proteins related to the RTX family of exoproteins. J Bacteriol (1993) 1.83
Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol (2000) 1.79
Hemorrhage, necrosis, and apoplexy in pituitary adenomas. Surg Neurol (1982) 1.79
SPG11 mutations are common in familial cases of complicated hereditary spastic paraplegia. Neurology (2008) 1.79
Development of child-centered disease-specific questionnaires for living with asthma. Psychosom Med (1994) 1.78
The mouse and human homologs of DMC1, the yeast meiosis-specific homologous recombination gene, have a common unique form of exon-skipped transcript in meiosis. Nucleic Acids Res (1996) 1.75
Alpha-2 macroglobulin gene and Alzheimer disease. Nat Genet (1999) 1.73
Mutations in the murine homologue of the Menkes gene in dappled and blotchy mice. Nat Genet (1994) 1.71
Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. Neurology (2007) 1.71
Arterial injuries in transsphenoidal surgery for pituitary adenoma; the role of angiography and endovascular treatment. AJNR Am J Neuroradiol (1997) 1.68
Physicians and the animal-rights movement. N Engl J Med (1991) 1.66
Inherited prion disease with 144 base pair gene insertion. 2. Clinical and pathological features. Brain (1992) 1.66
Validation of a telephone questionnaire for Parkinson's disease. J Clin Epidemiol (1998) 1.65
Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol (1999) 1.65
Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology (2009) 1.64
Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology (1997) 1.63
Healthcare utilization and costs in managed care patients with Alzheimer's disease during the last few years of life. J Am Geriatr Soc (2001) 1.61
Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet (1998) 1.60
Single-day apolipoprotein E genotyping. J Neurosci Methods (1994) 1.59
Assessment of a DJ-1 (PARK7) polymorphism in Finnish PD. Neurology (2003) 1.59
Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry (2012) 1.57
Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology (1993) 1.57
Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem (2000) 1.56